Viking Therapeutics begins oral VK2735 maintenance dosing trial in obesity

The wire

1. 01Viking Therapeutics said on October 6, 2026 it started a trial of oral VK2735 maintenance dosing after initial weight reduction, also evaluating monthly and every-other-week subcutaneous regimens.
2. 02Maintenance dosing addresses the practical question of what patients take after the titration and weight-loss phase, a recurring issue for prescribers and payers.
3. 03VK2735 remains development stage; no efficacy data from this trial has been reported, and Viking's market capitalization stood at $3.3 billion.

From the source

Viking Therapeutics starts oral trial as Truist targets Viking Therapeutics stock at USD 87

Viking Therapeutics (ISIN US92686J1060) announced initiation of an oral VK2735 maintenance dosing trial for patients with obesity on October 6, 2026. Viking Therapeutics said the study will evaluate oral maintenance regimens after initial weight loss, while monthly and every-other-week subcutaneous regimens will also be evaluated. Truist Securities raised its target from USD 83.00 to USD 87.00 on